Non-ionic surfactant eye drops for dry eye treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome, such as immunosuppressive agents, often cause significant side effects and have limited efficacy, making them undesirable for long-term use, especially in elderly patients, who are the primary affected demographic.
Innovation Solution
An ophthalmic composition containing a non-ionic surfactant, specifically polyoxyl 35 castor oil, is used in concentrations ranging from 0.01 to 8 weight/volume % to treat and prevent dry eye symptoms, providing rapid relief and improving ocular surface integrity with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents are used to treat dry eye, then anti-inflammatory effect is improved, but side effects increase
Solution Approach 1:
The patent changes the active ingredient from immunosuppressive agents to non-ionic surfactants, fundamentally altering the chemical parameter of the treatment. This substitution maintains therapeutic efficacy for dry eye while eliminating the severe side effects associated with immunosuppressants such as anemia, leukopenia, and thrombocytopenia
Solution Approach 2:
The patent employs non-ionic surfactants which are safer, shorter-acting topical agents compared to systemic immunosuppressants. These surfactants provide localized treatment with minimal systemic absorption, effectively replacing long-term immunosuppressive therapy with safer, temporary topical applications
2Reliability
If immunosuppressive agents are used for severe dry eye, then treatment efficacy is improved, but patient compliance decreases
Solution Approach 1:
The patent transforms the treatment approach by using non-ionic surfactants with favorable safety profiles, enabling frequent administration without cumulative toxicity. This parameter change from immunosuppressants to surfactants allows elderly patients to maintain compliance while receiving effective treatment for severe dry eye
3Reliability
If cyclosporine is applied to treat dry eye, then anti-inflammatory effect is improved, but cell viability decreases
Solution Approach 1:
The patent introduces non-ionic surfactants as intermediary substances that provide anti-inflammatory benefits without the direct cytotoxic effects of cyclosporine. These surfactants act as mediators between the need for inflammation control and the preservation of corneal epithelial cell viability, avoiding apoptosis and cell death
Solution Approach 2:
The patent replaces cyclosporine with non-ionic surfactants that are safer for cellular health. These surfactants provide temporary anti-inflammatory action without the severe cytotoxicity of cyclosporine, allowing repeated applications that preserve cell viability while treating inflammation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces dry eye symptoms and signs, as measured by SANDE scores, and improves ocular surface health, demonstrating a clinically significant improvement in both symptom relief and ocular surface integrity with a low incidence of side effects.
Implementation Method 1
an ophthalmic composition comprising a non-ionic surfactant as active ingredient
Implementation Method 2
a non-ionic surfactant is present in an effective amount from 0.01 to 8 weight/volume % based on the total composition
Data Source
Figure 1~1C
Figure 2A~2B
AI summary
It is provided an ophthalmic composition, particularly formulated as eye drops, comprising a non-ionic surfactant as active ingredient, wherein the non-ionic surfactant is present in an effective amount from 0.01 to 8 weight/volume % based on the total composition, for use in treating or preventing dry eye and/or for relieving one or more symptoms and/or signs of dry eye. The ophthalmic composition exerts a rapid effect in treating dry eye symptoms and signs while having very low incidence of side effects.